Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ENLV NASDAQ:PYRGF NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.70$4.71$3.35▼$17.94$124.74M3.93225,772 shs210,923 shsENLVEnlivex Therapeutics$0.53$0.71$0.52▼$2.10$125.24M1.52343,697 shs568,981 shsPYRGFPyroGenesis Canada$0.14+0.1%$0.22$0.12▼$0.53$32.51M0.2457,927 shs13,070 shsSPROSpero Therapeutics$2.20$2.57$1.80▼$3.22$127.38M1.491.75 million shs629,508 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+19.00%+44.67%+32.56%-57.84%ENLVEnlivex Therapeutics0.00%-7.44%-33.26%-44.58%-53.31%PYRGFPyroGenesis Canada0.00%-0.14%-20.88%-62.83%-56.64%SPROSpero Therapeutics0.00%-2.65%-26.17%-9.47%-24.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.70$4.71$3.35▼$17.94$124.74M3.93225,772 shs210,923 shsENLVEnlivex Therapeutics$0.53$0.71$0.52▼$2.10$125.24M1.52343,697 shs568,981 shsPYRGFPyroGenesis Canada$0.14+0.1%$0.22$0.12▼$0.53$32.51M0.2457,927 shs13,070 shsSPROSpero Therapeutics$2.20$2.57$1.80▼$3.22$127.38M1.491.75 million shs629,508 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+19.00%+44.67%+32.56%-57.84%ENLVEnlivex Therapeutics0.00%-7.44%-33.26%-44.58%-53.31%PYRGFPyroGenesis Canada0.00%-0.14%-20.88%-62.83%-56.64%SPROSpero Therapeutics0.00%-2.65%-26.17%-9.47%-24.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70245.61% UpsideENLVEnlivex Therapeutics 2.00Hold$16.503,027.37% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ASPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest PYRGF, SPRO, ENLV, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/26/2026ENLVEnlivex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026ENLVEnlivex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/APYRGFPyroGenesis Canada$9.14M3.56N/AN/A($0.01) per share-14.44SPROSpero Therapeutics$54.77M2.33$0.15 per share14.46$1.05 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/AENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.04N/AN/AN/A-115.14%N/A-60.81%N/ASPROSpero Therapeutics$8.57M$0.249.17N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)Latest PYRGF, SPRO, ENLV, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SPROSpero Therapeutics-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.062.73%N/A25.00%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06ENLVEnlivex TherapeuticsN/A193.24193.24PYRGFPyroGenesis CanadaN/A0.600.50SPROSpero TherapeuticsN/A10.5010.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AENLVEnlivex Therapeutics1.02%PYRGFPyroGenesis Canada0.03%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AENLVEnlivex Therapeutics12.28%PYRGFPyroGenesis Canada47.68%SPROSpero Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.88 millionN/AN/AENLVEnlivex Therapeutics70237.38 million208.23 millionOptionablePYRGFPyroGenesis Canada90225.46 million96.34 millionNo DataSPROSpero Therapeutics15057.90 million56.22 millionOptionablePYRGF, SPRO, ENLV, and AARD HeadlinesRecent News About These CompaniesSpero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average - What's Next?July 1, 2026 | americanbankingnews.comSPRO Share News TodayJune 30, 2026 | uk.investing.comBiggest stock movers Thursday: INTC, KR, ACN, and moreJune 18, 2026 | seekingalpha.comSpero shares jump after FDA clears first oral carbapenem antibiotic for US market (SPRO)June 18, 2026 | msn.comGSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsJune 18, 2026 | zacks.comSpero Therapeutics, Inc.: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 18, 2026 | finanznachrichten.deFDA approves first oral carbapenem therapy for cUTIsJune 17, 2026 | thepharmaletter.comTUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 17, 2026 | globenewswire.comSpero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)June 10, 2026 | seekingalpha.comSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateMay 13, 2026 | globenewswire.comEsther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) StockMay 7, 2026 | insidertrades.comSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5, 2026 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSpero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 11, 2026 | seekingalpha.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $207,484.12 in StockFebruary 10, 2026 | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of StockFebruary 6, 2026 | insidertrades.comWhy Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 7.48%February 4, 2026 | aaii.comAFormer Spero execs fined by SEC over antibiotic efficacy claimsJanuary 20, 2026 | fiercebiotech.comFSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisDecember 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYRGF, SPRO, ENLV, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$5.70 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.61 -0.09 (-1.58%) As of 07/2/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Enlivex Therapeutics NASDAQ:ENLV$0.53 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.52 0.00 (-0.49%) As of 07/2/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.PyroGenesis Canada NASDAQ:PYRGF$0.14 +0.00 (+0.14%) As of 07/2/2026 03:51 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Spero Therapeutics NASDAQ:SPRO$2.20 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.15 -0.05 (-2.05%) As of 07/2/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
